Plasmodium Falciparum Malaria (Drug Resistant) Clinical Trial
Official title:
Triple Antimalarial Combination (Imatinib-DHA-PPQ) to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant Parasites
The purpose of this study is to provide a new drug combination for a better treatment of P. falciparum for a faster parasite clearance and to counteract artemisinin resistance.
According to WHO, resistance to artemisinin derivatives (ART) is emerging in many areas of
the Greater Mekong Region as a delayed parasite clearance following a standard treatment by
artemisinin combined therapy (ACT). Artemisinin resistance is often accompanied by the
resistance to the partner drugs such as piperaquine (PPQ), mefloquine (MEF), amodiaquine (AQ)
and lumefantrine (LF).
The slow and incomplete clearance of parasites following ACT treatment is considered to
permit the selection of resistant parasites.
The availability of new, more efficient treatments accelerating the clearance of parasites is
therefore needed to counteract the selection of ART resistant strains.
Imatinib (IMA) has been demonstrated to increase the efficacy of ART in a synergic fashion.
This positive effect is further potentiated by low concentrations of PPQ.
IMA is active both on the intra-erythrocyte asexual forms and on gametocytes. It is therefore
expected that the combination DHA-PPQ-IMA should lead to faster and radical clearance of the
parasites, therefore reducing the frequency of healthy carriers and transmission.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03726593 -
Drug Combinations of Atovaquone-Proguanil (AP) With ACT
|
Phase 4 |